$VRCA News

Verrica Pharmaceuticals Q2 Earnings Call Highlights

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

Verrica Pharmaceuticals Inc. Q1 2026 Earnings Call Summary

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call

Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call

Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Verrica Pharmaceuticals Q1 Earnings Call Highlights

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum